Gene Delivery of Sarcoplasmic Reticulum Calcium ATPase Inhibits Ventricular Remodeling in Ischemic Mitral Regurgitation
Overview
Authors
Affiliations
Background: Mitral regurgitation (MR) doubles mortality after myocardial infarction (MI). We have demonstrated that MR worsens remodeling after MI and that early correction reverses remodeling. Sarcoplasmic reticulum Ca(+2)-ATPase (SERCA2a) is downregulated in this process. We hypothesized that upregulating SERCA2a might inhibit remodeling in a surgical model of apical MI (no intrinsic MR) with independent MR-type flow.
Methods And Results: In 12 sheep, percutaneous gene delivery was performed by using a validated protocol to perfuse both the left anterior descending and circumflex coronary arteries with occlusion of venous drainage. We administered adeno-associated virus 6 (AAV6) carrying SERCA2a under a Cytomegalovirus promoter control in 6 sheep and a reporter gene in 6 controls. After 2 weeks, a standardized apical MI was created, and a shunt was implanted between the left ventricle and left atrium, producing regurgitant fractions of ≈30%. Animals were compared at baseline and 1 and 3 months by 3D echocardiography, Millar hemodynamics, and biopsies. The SERCA2a group had a well-maintained preload-recruitable stroke work at 3 months (decrease by 8±10% vs 42±12% with reporter gene controls; P<0.001). Left ventricular dP/dt followed the same pattern (no change vs 55% decrease; P<0.001). Left ventricular end-systolic volume was lower with SERCA2a (82.6±9.6 vs 99.4±9.7 mL; P=0.03); left ventricular end-diastolic volume, reflecting volume overload, was not significantly different (127.8±6.2 vs 134.3±9.4 mL). SERCA2a sheep showed a 15% rise in antiapoptotic pAkt versus a 30% reduction with the reporter gene (P<0.001). Prohypertrophic activated STAT3 was also 41% higher with SERCA2a than in controls (P<0.001). Proapoptotic activated caspase-3 rose >5-fold during 1 month in both SERCA2a and control animals (P=NS) and decreased by 19% at 3 months, remaining elevated in both groups.
Conclusions: In this controlled model, upregulating SERCA2a induced better function and lesser remodeling, with improved contractility, smaller volume, and activation of prohypertrophic/antiapoptotic pathways. Although caspase-3 remained activated in both groups, SERCA2a sheep had increased molecular antiremodeling "tone." We therefore conclude that upregulating SERCA2a inhibits MR-induced post-MI remodeling in this model and thus may constitute a useful approach to reduce the vicious circle of remodeling in ischemic MR.
Mazurek R, Tharakan S, Mavropoulos S, Singleton D, Bikou O, Sakata T Nat Commun. 2024; 15(1):10450.
PMID: 39617804 PMC: 11609281. DOI: 10.1038/s41467-024-54635-x.
Farraha M, Barry M, Lu J, Pouliopoulos J, Le T, Igoor S Gene Ther. 2019; 26(9):399-406.
PMID: 31467408 DOI: 10.1038/s41434-019-0097-0.
New therapies for the treatment of heart failure: a summary of recent accomplishments.
Machaj F, Dembowska E, Rosik J, Szostak B, Mazurek-Mochol M, Pawlik A Ther Clin Risk Manag. 2019; 15:147-155.
PMID: 30774351 PMC: 6348963. DOI: 10.2147/TCRM.S179302.
Vinogradova T, Sirenko S, Lakatta E Int J Mol Sci. 2018; 19(8).
PMID: 30044420 PMC: 6121616. DOI: 10.3390/ijms19082173.
Katz M, Fargnoli A, Weber T, Hajjar R, Bridges C Hum Gene Ther Clin Dev. 2017; 28(3):157-164.
PMID: 28726495 PMC: 5655838. DOI: 10.1089/humc.2017.070.